drugset / Trial / NCT03377257

Efficacy and Safety of Zolmitriptan by Sublingual Administration

NCT03377257

Phase 4 Unknown 71 enrolled Xijing Hospital
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose is to evaluate the effectiveness and safety profile of zolmitriptan by Sublingual administration for the acute treatment of Cluster headache.

Timeline

Start
2018-01-01
Primary completion
2018-12-31
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolmitriptan Small molecule 2.5 mg Other